Business
Manhattan Scientifics Completes Licensing Deal for its Patented Metals Nanotechnology
Manhattan Scientifics Completes Licensing Deal for its Patented Metals Nanotechnology.
About this update from Manhattan Scientifics, Inc.
[{"type":"text","content":"\n \n Manhattan Scientifics Inc. (MHTX: OTCQ: BB), is pleased to announce that \n the company has completed an exclusive license and transfer of specialty \n machines to a large American metals manufacturer who provides specialty \n metals to the U.S. and global medical industry. The proprietary \n technology is designed to substantially improve and strengthen the \n bonding of medical prosthetics to human bone.\n \n \n The global prosthetics and orthotics market size is estimated at $8.15 \n billion. The Company’s client serves multiple markets including vascular \n therapy, cardiac rhythm management, endoscopy, orthopedics, dental, and \n neuromodulation. FDA approval has been granted for use of these new \n alloys in its initial dental application.\n \n \n The transaction involves 7-figure payments to the Company staged over a \n 4 year period, in addition to royalty payments on sales made.\n \n \n Manhattan Scientifics is a technology developer working closely with the \n Los Alamos National Laboratory. The company is dedicated to \n commercializing disruptive technologies. Previously, its founder, Marvin \n Maslow, working closely with U.S. Dept of Defense, DARPA, financed and \n commercialized the development of HDTV.\n \n \n Mr. Maslow, Manhattan’s Founder and Chairman said, “Our Company \n is focused on commercializing nanotechnologies. Our nanometals are 'new' \n and early in development. They have yet to be proven practical for large \n scale commercial use. We’ve placed them in very strong hands, with \n skilled manufacturing and an extensive sales and marketing team calling \n on the medical industry.”\n \n \n Manny Tsoupanarias, CEO, added, “One year ago we spun out our 2nd \n nanotechnology, an early cancer diagnostic and took it public on the \n Australian Stock Exchange (IBX.AX). \n Manhattan Scientifics owns 64 million shares of IBX. Our goal is to \n create wealth for our 5,000 shareholders and to follow with a large \n acquisition and to up-list to the NASDAQ exchange. The cancer diagnostic \n company Imagion \n Biosystems, is 'partnered' with M.D. Anderson Cancer Center, \n Houston.”\n \n \n About Manhattan Scientifics, Inc.Manhattan Scientifics Inc. \n (www.mhtx.com) \n is located in New Mexico, New York and Montreal. It is focused on \n technology transfer and comme...